Alogliptin (SYR322)

Description: Alogliptin (formerly also known as SYR-322; trade names Nesina; Kazano, Oseni) is a novel, potent, orally bioavailable, and selective inhibitor of DPP-4 (serine protease dipeptidyl peptidase IV) with potential anti-hyperglycemic activity. It inhibits DPP-4 with an IC50 value of 2.6 nM, and exhibits > 10, 000-fold selectivity for inhibiting DPP-4 over the closely related DPP isoforms such as DPP-8 and DPP-9. It is an anti-diabetic drug marketed in Japan since 2010; and in 2013, the FDA approved the drug in three formulations: as a stand-alone with the brand-name Nesina, combined with metformin using the name Kazano, and when combined with pioglitazone as Oseni. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke.

References: J Med Chem. 2007 May 17; 50(10):2297-300; Life Sci. 2009 Jul 17; 85(3-4):122-6.

Related CAS: 850649-62-6 (benzoate); 1246817-18-4 Alogliptin (13CD3

Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

InChi Key: ZSBOMTDTBDDKMP-OAHLLOKOSA-N

InChi Code: 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3, 5-6, 9, 15H, 4, 7-8, 11-12, 20H2, 1H3/t15-/m1/s1

SMILES Code: n1(c(=O)cc(n(c1=O)Cc1c(cccc1)C#N)N1C[CH](CCC1)N)C